DEFTA Partners

Endogena is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs. Endogena's approach has the potential of a paradigm shift to treat degenerative conditions related to ageing and genetic disorders. The company implements innovation in the field of regenerative medicine. Their science combines the latest developments in stem cell biology, AI, and expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases.

DiA Imaging Analysis Ltd. specializes in AI-driven ultrasound analysis technology aimed at enhancing cardiac function diagnostics. Established in 2009 and based in Beersheba, Israel, the company provides a suite of automated tools, including LVivo EF for ejection fraction evaluation, LVivo RV for right ventricle analysis, and LVivo Strain for assessing myocardial strain. These solutions address common challenges faced by clinicians, such as obtaining optimal images and accurately analyzing them for clinical abnormalities. DiA's products, which can be integrated into any ultrasound device or healthcare IT system, also include LVivo SAX for detecting coronary heart disease and LVivo Mobile for mobile ultrasound analysis. The company holds regulatory clearances for its cardiac toolbox and serves a global user base, reflecting its commitment to making ultrasound analysis smarter and more accessible.

InformAI, LLC specializes in developing business analytics and artificial intelligence solutions tailored for the healthcare industry. Founded in 2017 and headquartered in Houston, Texas, the company offers a range of AI-powered tools designed to enhance diagnostic accuracy and operational efficiency for healthcare organizations, medical device companies, and imaging firms. Their product suite includes classifiers for conditions such as brain cancer and paranasal sinus diseases, as well as surgical risk and patient outcome predictors. InformAI's software leverages advanced algorithms, including deep learning and natural language processing, to streamline image classification and analyze medical reports. By providing these innovative solutions, InformAI aims to facilitate quicker patient diagnoses and improve overall healthcare outcomes.

Acepodia is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer treatment. Utilizing its proprietary Antibody-Cell Conjugation (ACC) platform, Acepodia creates first-in-class therapies by directly attaching tumor-targeting antibodies to immune cell receptors. This method enhances the interaction between immune cells and cancer cells, resulting in highly specific and potent therapies without the need for genetic engineering. Acepodia is dedicated to advancing immunotherapeutic approaches in oncology, with a diverse pipeline targeting various cancer types. The company aims to make these effective treatments broadly accessible to patients.

Endogena is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs. Endogena's approach has the potential of a paradigm shift to treat degenerative conditions related to ageing and genetic disorders. The company implements innovation in the field of regenerative medicine. Their science combines the latest developments in stem cell biology, AI, and expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases.

Aegle Therapeutics Corporation is a biotechnology company focused on developing innovative therapies using extracellular vesicles (EVs) derived from allogeneic bone marrow-derived mesenchymal stem cells. Established in 2019 and headquartered in Arlington, Massachusetts, with an additional office in Miami, the company aims to address dermatological conditions, particularly dystrophic epidermolysis bullosa, a rare pediatric skin disorder characterized by blistering. Aegle's proprietary technology isolates EVs in a cell-free manner, allowing for a safer and potentially more cost-effective approach to harnessing the regenerative properties of stem cells. The company’s EV therapy is designed to enhance healing, reduce scarring, and improve the overall appearance of affected tissues. Aegle has received FDA clearance for its Investigational New Drug application for dystrophic epidermolysis bullosa and anticipates entering clinical trials in the near future.

InformAI, LLC specializes in developing business analytics and artificial intelligence solutions tailored for the healthcare industry. Founded in 2017 and headquartered in Houston, Texas, the company offers a range of AI-powered tools designed to enhance diagnostic accuracy and operational efficiency for healthcare organizations, medical device companies, and imaging firms. Their product suite includes classifiers for conditions such as brain cancer and paranasal sinus diseases, as well as surgical risk and patient outcome predictors. InformAI's software leverages advanced algorithms, including deep learning and natural language processing, to streamline image classification and analyze medical reports. By providing these innovative solutions, InformAI aims to facilitate quicker patient diagnoses and improve overall healthcare outcomes.

TARA Biosystems, Inc. is a biotechnology company focused on developing organ-on-a-chip technology, specifically human cardiac tissue models, to enhance drug discovery and safety assessments. Founded in 2014 and based in the United States, the company utilizes stem cell-derived cardiac tissue that mimics adult physiological conditions, enabling precise measurement of cardiac functionality. This innovative platform aims to facilitate the faster and safer development of new therapies by providing predictive in vitro models that can assess the effects of drug compounds on heart function without the need for human testing. Through its advanced technology, TARA Biosystems seeks to improve the health of patients by enabling more reliable assessments of cardiac drug efficacy and safety.

1World Online, Inc. is a developer of a consumer intelligence platform designed to enhance user engagement and drive revenue for publishers and advertisers. Founded in 2011 and headquartered in Redwood City, California, with additional offices across various global locations, the platform allows users to create polls, quizzes, surveys, and trivia. This functionality not only increases reader interaction but also provides valuable advertising opportunities. By leveraging artificial intelligence, 1World Online enables businesses to gain insights into their audiences, improving their ability to profile and monetize them effectively. The platform also supports editors and journalists by providing timely news content, allowing for better-targeted stories and fostering improved relationships with readers.

Aegle Therapeutics Corporation is a biotechnology company focused on developing innovative therapies using extracellular vesicles (EVs) derived from allogeneic bone marrow-derived mesenchymal stem cells. Established in 2019 and headquartered in Arlington, Massachusetts, with an additional office in Miami, the company aims to address dermatological conditions, particularly dystrophic epidermolysis bullosa, a rare pediatric skin disorder characterized by blistering. Aegle's proprietary technology isolates EVs in a cell-free manner, allowing for a safer and potentially more cost-effective approach to harnessing the regenerative properties of stem cells. The company’s EV therapy is designed to enhance healing, reduce scarring, and improve the overall appearance of affected tissues. Aegle has received FDA clearance for its Investigational New Drug application for dystrophic epidermolysis bullosa and anticipates entering clinical trials in the near future.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Fort Worth, Texas, with an additional office in Dublin, Ireland. The company focuses on developing novel therapeutics that target Glycogen Synthase Kinase-3β (GSK-3β) for the treatment of various conditions, including Alzheimer’s disease, bipolar disorder, type II diabetes, inflammatory diseases, and several high-impact cancers such as glioblastoma, ovarian, breast, and pancreatic cancers. Actuate is advancing its lead compound, elraglusib (formerly known as 9-ING-41), which is designed to inhibit GSK-3β and disrupt cancer cell survival and growth. The company has demonstrated promising anti-tumor activity in preclinical models, particularly for difficult-to-treat cancers. Actuate Therapeutics aims to discover, develop, and commercialize new therapeutic agents that address significant unmet medical needs in oncology and neurodegeneration.

BioEclipse Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California, focused on developing curative immuno-oncology therapeutics for cancer patients. The company’s flagship product, CRX-100, represents a novel combination therapy that enhances the immune system's ability to combat cancer without the need to reengineer patients' cells. By utilizing a proprietary approach that combines activated immune cells with an adapted oncolytic virus, BioEclipse Therapeutics aims to selectively target and destroy malignant cells while improving tumor visibility to the immune system. The company's mission is to advance clinical outcomes and enhance the quality of life for cancer patients, with the ultimate goal of transforming cancer into a curable disease. BioEclipse Therapeutics was established in 2006 and was previously known as ConcentRx Inc before rebranding in 2017.

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Fort Worth, Texas, with an additional office in Dublin, Ireland. The company focuses on developing novel therapeutics that target Glycogen Synthase Kinase-3β (GSK-3β) for the treatment of various conditions, including Alzheimer’s disease, bipolar disorder, type II diabetes, inflammatory diseases, and several high-impact cancers such as glioblastoma, ovarian, breast, and pancreatic cancers. Actuate is advancing its lead compound, elraglusib (formerly known as 9-ING-41), which is designed to inhibit GSK-3β and disrupt cancer cell survival and growth. The company has demonstrated promising anti-tumor activity in preclinical models, particularly for difficult-to-treat cancers. Actuate Therapeutics aims to discover, develop, and commercialize new therapeutic agents that address significant unmet medical needs in oncology and neurodegeneration.

Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.

Savonix, Inc. is a San Francisco-based company that specializes in developing a digital neuro-cognitive assessment and brain health platform. Founded in 2014, its flagship product, Savonix Mobile, allows users to perform clinically recognized cognitive assessments on mobile devices. This platform provides accessible tests covering various cognitive domains, such as memory and implicit learning, which are guided by virtual clinicians. Savonix's assessments are designed to help healthcare providers, researchers, and insurers understand cognitive risks, including those related to dementia, and to inform treatment planning and diagnosis. The company has established strategic partnerships with notable institutions, including New York University and several biotech firms. Unique features of the platform include a 3D gaming component that generates additional cognitive insights without requiring separate tests, enhancing the understanding of cognitive function in aging populations. Savonix aims to deliver an affordable, scalable, and actionable solution for monitoring cognitive health, making it a leader in the field of digital cognitive assessment.

Touchence, Inc. is a technology company based in Taito, Japan, founded in 2011. The company specializes in developing and manufacturing innovative tactile sensors designed for data collection in robotics and artificial intelligence applications. Their sensors, made from a foam-like material, can be touched and pinched, responding to interaction and pressure in three dimensions. This unique capability allows robot manufacturers to integrate soft sensors into their products, enhancing the user experience by making interactions with robots feel more natural. Touchence offers a comprehensive service for businesses seeking to incorporate these advanced tactile sensor solutions into their technologies.

DiA Imaging Analysis Ltd. specializes in AI-driven ultrasound analysis technology aimed at enhancing cardiac function diagnostics. Established in 2009 and based in Beersheba, Israel, the company provides a suite of automated tools, including LVivo EF for ejection fraction evaluation, LVivo RV for right ventricle analysis, and LVivo Strain for assessing myocardial strain. These solutions address common challenges faced by clinicians, such as obtaining optimal images and accurately analyzing them for clinical abnormalities. DiA's products, which can be integrated into any ultrasound device or healthcare IT system, also include LVivo SAX for detecting coronary heart disease and LVivo Mobile for mobile ultrasound analysis. The company holds regulatory clearances for its cardiac toolbox and serves a global user base, reflecting its commitment to making ultrasound analysis smarter and more accessible.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

1World Online, Inc. is a developer of a consumer intelligence platform designed to enhance user engagement and drive revenue for publishers and advertisers. Founded in 2011 and headquartered in Redwood City, California, with additional offices across various global locations, the platform allows users to create polls, quizzes, surveys, and trivia. This functionality not only increases reader interaction but also provides valuable advertising opportunities. By leveraging artificial intelligence, 1World Online enables businesses to gain insights into their audiences, improving their ability to profile and monetize them effectively. The platform also supports editors and journalists by providing timely news content, allowing for better-targeted stories and fostering improved relationships with readers.

MeeVee is an online platform that specializes in providing personalized TV guides, allowing users to curate their viewing experience based on their interests. By selecting favorite actors, genres, or specific keywords, users receive customized listings of upcoming programming that align with their preferences. The service continuously updates these listings, ensuring users are informed about relevant shows and movies until they choose to change their interests. MeeVee also offers summaries, episode trailers, and detailed information about various TV shows across numerous cable and satellite channels, all at no cost to the user. Additionally, the MeeVee Guide widget can be integrated into other websites, enabling visitors to access personalized TV listings directly from those pages. This approach creates a tailored web experience, moving away from traditional, universal TV grids.

MeeVee is an online platform that specializes in providing personalized TV guides, allowing users to curate their viewing experience based on their interests. By selecting favorite actors, genres, or specific keywords, users receive customized listings of upcoming programming that align with their preferences. The service continuously updates these listings, ensuring users are informed about relevant shows and movies until they choose to change their interests. MeeVee also offers summaries, episode trailers, and detailed information about various TV shows across numerous cable and satellite channels, all at no cost to the user. Additionally, the MeeVee Guide widget can be integrated into other websites, enabling visitors to access personalized TV listings directly from those pages. This approach creates a tailored web experience, moving away from traditional, universal TV grids.

MeeVee is an online platform that specializes in providing personalized TV guides, allowing users to curate their viewing experience based on their interests. By selecting favorite actors, genres, or specific keywords, users receive customized listings of upcoming programming that align with their preferences. The service continuously updates these listings, ensuring users are informed about relevant shows and movies until they choose to change their interests. MeeVee also offers summaries, episode trailers, and detailed information about various TV shows across numerous cable and satellite channels, all at no cost to the user. Additionally, the MeeVee Guide widget can be integrated into other websites, enabling visitors to access personalized TV listings directly from those pages. This approach creates a tailored web experience, moving away from traditional, universal TV grids.

Fortinet is a cybersecurity company based in California that specializes in network security appliances and a comprehensive range of security solutions, including cloud security, zero-trust access, and security operations. The company serves a diverse clientele, including enterprises, managed service providers, and telecommunications carriers, and is known for its ability to deliver high levels of security while minimizing total ownership costs. With over 700,000 customers globally, Fortinet primarily generates revenue through its subscription and support services, providing a flexible and scalable path for expansion in the ever-evolving cybersecurity landscape.

Fortinet is a cybersecurity company based in California that specializes in network security appliances and a comprehensive range of security solutions, including cloud security, zero-trust access, and security operations. The company serves a diverse clientele, including enterprises, managed service providers, and telecommunications carriers, and is known for its ability to deliver high levels of security while minimizing total ownership costs. With over 700,000 customers globally, Fortinet primarily generates revenue through its subscription and support services, providing a flexible and scalable path for expansion in the ever-evolving cybersecurity landscape.

As of June 11, 2007, BroadWare Technologies, Inc. was acquired by Cisco Systems, Inc. BroadWare Technologies, Inc., a network video systems company, engages in the development and delivery of platforms and end-to-end browser-based solutions for collecting, recording, routing, and managing live and archived surveillance video. It offers Media Platform, a suite of server-based technologies for management, distribution, and storage of video surveillance data in a network environment; and Application Server, which enables users to determine levels of authority for viewing cameras, creating or viewing archives, and controlling movable cameras. The company offers Command Server, a digital matrix switch that allows each operator and intelligent application to control the video being displayed on various monitors; and Media Server that enables distribution, archiving, and management of video feeds. In addition, BroadWare Technologies provides specialty professional services, education and training, and support services. The company provides its products for use in applications, such as military bases, unmanned vehicles, embassies, corrections, border control, perimeter montoring, law enforcement, airports and seaports, homeland security, traffic montoring, and public infrastructure montoring, as well as corporate security, retail, public transit systems, gaming, health care, colleges and universities monitoring, petro-chemical, utlitites, and financial services. It serves airports and seaports, transportation systems, and various federal agencies and military branches. The company, formerly known as Graham Technology Solutions, was founded in 1995 and is headquartered in Santa Clara, California.

Fortinet is a cybersecurity company based in California that specializes in network security appliances and a comprehensive range of security solutions, including cloud security, zero-trust access, and security operations. The company serves a diverse clientele, including enterprises, managed service providers, and telecommunications carriers, and is known for its ability to deliver high levels of security while minimizing total ownership costs. With over 700,000 customers globally, Fortinet primarily generates revenue through its subscription and support services, providing a flexible and scalable path for expansion in the ever-evolving cybersecurity landscape.

Oplus Technologies Ltd., a fabless semiconductor company, designs, develops, and markets integrated circuit display processors and software solutions for the digital display market. It offers multimedia display and video processors for flat panel plasma and LCD displays, TVs, projection systems, LCD monitors, and digital display applications. The company also provides system-on-chip solutions. It serves consumer electronics companies and display device manufacturers in Israel and internationally. Oplus Technologies Ltd. was founded in 1993 and is headquartered in Yokneam, Israel.

SourceGate Systems develops a managed service tailored for Internet Service Providers (ISPs) to enhance their subscription-based revenue models through advertising-based revenue streams. The company's internet-based content delivery system allows ISPs to offer personalized, content-rich services to their customers, thereby providing additional avenues for revenue generation. By focusing on the needs of ISPs, SourceGate Systems aims to support their clients in diversifying income sources while improving customer engagement.

Intraspect Software specializes in inter-enterprise solutions that enhance collaborative business processes. Founded in 1995 and acquired by Vignette in 2003, the company offers portal collaboration tools that allow users to create shared communities focused on strategic accounts, products, and business processes. Its flagship product, Intraspect 5.5, features architectural improvements suited for inter-enterprise deployments, while C-mail Services facilitate user interaction with Intraspect solutions through effective communication channels. The company’s software is particularly beneficial for industries such as financial services and high technology, enabling cross-functional teams to collaborate and communicate effectively with customers, suppliers, and partners across various organizational and geographic boundaries.